📰 Nasdaq Pcvx News
Page 2 - Nasdaq Pcvx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Pcvx. Real-time updates on events, politics, business and more.
February 6, 2024
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $73.87, for a total transaction of $123,141.29. Following the transaction, the senior vice president now owns 20,710 shares in the company, valued […]
February 4, 2024
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) Director Heath Lukatch sold 5,000 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $71.50, for a total transaction of $357,500.00. Following the completion of the sale, the director now directly owns 5,625 shares in the […]
February 3, 2024
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
February 2, 2024
Victory Capital Management Inc. cut its holdings in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 6.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 430,949 shares of the company’s stock after selling 31,355 shares during the quarter. Victory Capital Management […]
January 31, 2024
Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $67.35, but opened at $70.60. Vaxcyte shares last traded at $69.57, with a volume of 403,300 shares trading hands. Wall Street Analyst Weigh In Several brokerages have recently weighed in on […]
January 29, 2024
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...
January 29, 2024
Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $66.48 and last traded at $66.41, with a volume of 180384 shares traded. The stock had previously closed at $64.31. Analyst Ratings Changes A number of analysts recently commented on […]
January 29, 2024
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report)’s share price hit a new 52-week high on Monday . The company traded as high as $66.48 and last traded at $66.41, with a volume of 180384 shares trading hands. The stock had previously closed at $64.31. Analyst Upgrades and Downgrades A number of brokerages recently weighed in […]
December 12, 2023
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) SVP Mikhail Eydelman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $56.50, for a total value of $565,000.00. Following the transaction, the senior vice president now directly owns 21,035 shares in […]
December 10, 2023
Mizuho initiated coverage on shares of Vaxcyte (NASDAQ:PCVX – Free Report) in a report issued on Thursday, MarketBeat.com reports. The brokerage issued a buy rating and a $69.00 price target on the stock. Several other equities research analysts have also recently issued reports on the stock. Needham & Company LLC reissued a buy rating and […]